Oral edible plant vaccine containing hypoallergen of American cockroach major allergen Per a 2 prevents roach-allergic asthma in a murine model

Abstract

BackgroundAmerican cockroaches (Periplaneta americana) are an important indoor allergen source and a major risk factor for exacerbations and poor control of asthma. We previously reported that allergen components from American cockroaches exhibit varying levels of pathogenicity. Sensitization to major American cockroach allergen, Per a 2, correlated with more severe clinical phenotypes among patients with allergic airway diseases.Materials and methodsIn this study, we examined whether oral plant vaccine-encoding full-length Per a 2 clone-996 or its hypoallergenic clone-372 could exert a prophylactic role in Per a 2-sensitized mice. The cDNAs coding Per a 2–996 and Per a 2–372 were inserted into TuMV vector and expressed in Chinese cabbage. Adult female BALB/c mice were fed with the cabbage extracts for 21 days and subsequently underwent two-step sensitization with recombinant Per a 2.ResultsPer a 2-specific IgE measured by in-house ELISA in the sera of Per a 2-372-treated groups were significantly lower than in the control groups after allergen challenge but not the Per a 2-996-treated group. Moreover, Per a 2–372 vaccine markedly decreased airway hyper-responsiveness and infiltration of inflammatory cells into the lungs, as well as reduced mRNA expression of IL-4 and IL-13 in comparison with the control mice.ConclusionOur data suggest that oral administration of edible plant vaccine encoding Per a 2 hypo-allergen may be used as a prophylactic strategy against the development of cockroach allergy.

The allergenic activity and clinical impact of individual IgE-antibody binding molecules from indoor allergen sources

“…123 In a study from Taiwan, in a mouse model of asthma, oral treatment with Per a 2 expressed in Chinese cabbage, from an hypoallergenic partial clone Per a 2-372, blunt the development of allergen-specific IgE and IL-4 mRNA expression after challenge with intranasal Per a 2, and had preventive effects on airway hyperresponsiveness and inflammation. 124 Group 3 and 4…”

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?

“…The fact that plant-based vaccine formulations will not require antigen purification will be, without a doubt, the main factor that will make them low-cost alternatives [52], which is necessary to provide wide vaccination coverage in developing and low-income countries. Recent promising reports in the viability of formulating oral vaccines include the case of the Hepatitis B virus surface antigen [53] and models of immunotherapy against allergy with promising results [54], among other diseases.…”

A Comprehensive Overview on the Production of Vaccines in Plant-Based Expression Systems and the Scope of Plant Biotechnology to Combat against SARS-CoV-2 Virus Pandemics

“…Plant biotechnology-based vaccines are becoming a reality, even though their progress has been slower than expected. It is particularly true in oral vaccines, having the main drawbacks of poor reproducibility, a question mark in antigen stability, and bioavailability [128,129].…”